Such a result is in line with the ‘stress-response’ role of the two molecules: tumors highly expressing c-Met and YKL-40 will most likely not benefit from CRT because these cancer cells have already switched on a transcriptional adaptation to unfavorable microenviromental conditions. This evidence concerns the gene MET and cancer.